Davis R M Inc. Purchases 712 Shares of Eli Lilly and Company $LLY

Davis R M Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,999 shares of the company’s stock after acquiring an additional 712 shares during the quarter. Davis R M Inc.’s holdings in Eli Lilly and Company were worth $56,105,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter worth about $25,000. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $25,000. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $30,000. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Neutral Sentiment: Eli Lilly confirmed it will report second-quarter 2026 results on August 5, with a conference call the same day, keeping attention on the company’s upcoming earnings update. Lilly confirms date and conference call for second-quarter 2026 financial results announcement
• Neutral Sentiment: An update on Lilly’s EMPRISE diabetes study added some interest in the company’s clinical data pipeline, but the market’s focus is still centered on the legal battle with Novo Nordisk. Real-World Diabetes Data: What Eli Lilly’s EMPRISE Update Means for LLY Investors
• Positive Sentiment: Broader pharma stocks got a lift after reports that generic drugs imported into the U.S. will remain under a zero-percent tariff for two more years, which could support sentiment across the sector, including Lilly. These major drug stocks rally after Trump’s zero tariff announcement

Analyst Upgrades and Downgrades

Several research firms recently commented on LLY. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. Royal Bank Of Canada raised their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Morgan Stanley boosted their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Finally, Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,163.70 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The stock has a market cap of $1.10 trillion, a PE ratio of 41.34, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The stock has a fifty day moving average of $1,129.17 and a 200-day moving average of $1,038.31.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the prior year, the firm posted $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 34.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.